Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 2/2012

01-04-2012 | PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Pediatric Vasculitis

Authors: Ezgi Deniz Batu, Seza Ozen

Published in: Current Rheumatology Reports | Issue 2/2012

Login to get access

Abstract

The primary systemic vasculitides in childhood are quite rare except for Henoch-Schönlein purpura and Kawasaki disease. These are usually self-limited diseases. The etiopathogenesis for most of them is not clearly understood. However, it is usually thought that environmental triggers (mostly infectious) evoke an aggravated inflammatory response in susceptible individuals. The classification criteria for most of them were recently validated for children. Clinical manifestations are determined by the organs affected, reflecting the involved vessels on a background of constitutional symptoms. For treatment, the main data are adapted from adult studies, especially for rarer vasculitides in childhood. In this review, the recent classification criteria, current pathophysiologic pathways, and treatment protocols are summarized.
Literature
1.
Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr Rheumatol Rep. 2000;2:411–6.PubMedCrossRef
2.
Rowley AH, Ozen S, Sundel RP, et al. A clinician’s pearls and myths in rheumatology. London: Springer; 2009. p. 219–29.CrossRef
3.
4.
Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterization. Ann Rheum Dis. 2010;69:790–7.PubMedCrossRef
5.
•• Ozen S, Pistoiro A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798–806. This is the criteria validation for most of the vasculitides in childhood. PubMedCrossRef
6.
Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PRES endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41.PubMedCrossRef
7.
Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children. Am J Dis Child. 1960;99:833–54.
8.
9.
10.
Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. 2007;22:2067–72.PubMedCrossRef
11.
Kawasaki Y, Suyama K, Yugeta E, et al. The incidence and severity of Henoch-Schönlein purpura nephritis over a 22-year period in Fukushima prefecture, Japan. Int Urol Nephrol. 2010;42:1023–9.PubMedCrossRef
12.
Kawasaki Y. The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis. Clin Exp Nephrol 2011, In press.
13.
Shin JI, Song KS, Kim H, et al. The gene expression profile of matrix metalloproteinases and their inhibitors in children with Henoch-Schönlein purpura. Br Assoc Dermatol. 2011;164:1348–55.CrossRef
14.
Chen T, Guo Z-P, Li M-M, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schönlein purpura. Clinical and Experimental Immunology 2011, In press.
15.
Brogan P, Bagga A. Leukocytoclastic vasculitis. In: Cassidy JT, Petty RE, Laxer RM, et al., editors. Textbook of pediatric rheumatology. Philadelphia: Saunders Elsevier; 2011. p. 482–97.
16.
Roberts PF, Waller TA, Brinker TM, et al. Henoch-Schönlein purpura: a review article. South Med J. 2007;100(8):821–4.PubMedCrossRef
17.
Chen S-Y, Kong M-S. Gastrointestinal manifestations and complications of Henoch-Schönlein purpura. Chang Gung Med. 2004;27:175–81.
18.
Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90:916–20.PubMedCrossRef
19.
20.
Rostoker G. Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001;15(2):99–138.PubMedCrossRef
21.
Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol. 2002;16(3):411–25.PubMed
22.
•• Davin J-C. Henoch-Schönlein purpura nephritis: pathophysiology, treatment and future strategy. Clin J Am Soc Nephrol. 2011;6:679–89. This is an excellent review describing the treatment strategies on pathogenetic pathways in HSP. PubMedCrossRef
23.
Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schönlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol. 1998;49(1):9–14.PubMed
24.
Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch-Schönlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001;21:128–33.PubMedCrossRef
25.
Goldstein AR, White RHR, Akuse R, et al. Long term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992;339:280–2.PubMedCrossRef
26.
Wakaki H, Ishikura K, Hataya H, et al. Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol. 2011;26:921–5.PubMedCrossRef
27.
28.
De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301–8.PubMed
29.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708–33.PubMedCrossRef
30.
31.
Yanagawa H, Nakamura Y, Kawasaki T, et al. Nationwide epidemics of Kawasaki disease in Japan during winter of 1985–86. Lancet. 1986;2(8516):1138–9.PubMedCrossRef
32.
Burgner D, Davilla S, Breunis WB, et al. International Kawasaki Disease Genetic Consortium: a genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PloS Genet. 2009;5(1):e1000319.PubMedCrossRef
33.
Oh JH, Han JW, Lee SJ, et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr Cardiol. 2008;29:402–8.PubMedCrossRef
34.
Hsieh Y-Y, Lin Y-J, Chang C-C, et al. Human lymphocyte antigen B-associated transcripts 2,3 and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm. J Clin Lab Anal. 2010;24:262–8.PubMedCrossRef
35.
Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr. 2009;168:157–62.PubMedCrossRef
36.
Levy M, Karen G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J. 1990;9:122–6.PubMedCrossRef
37.
Pinna GS, Kafetzis DA, Tselkas OI, et al. Kawasaki disease: an overview. Curr Opin Infect Dis. 2008;21:263–70.PubMedCrossRef
38.
Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010;9:441–8.PubMedCrossRef
39.
•• Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol. 2011;In press. This is the most recent review defining clearly the challenges in KD.
40.
Tse SM, Silverman ED, Mc Crindle BW, et al. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr. 2002;140:450–5.PubMedCrossRef
41.
Sugahara Y, Ishii M, Muta H, et al. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol. 2008;29:398–401.PubMedCrossRef
42.
Furukawa T, Kishiro M, Akimoto M, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93:142–6.PubMedCrossRef
43.
McCrindle BW. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. 2009;120:6–8.PubMedCrossRef
44.
Ozen S, Bakkaloglu A, Dusunsel R, et al. Childhood vasculitis in Turkey: a nationwide survey. Clin Rheumatol. 2007;26:196–200.PubMed
45.
Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145:517–22.PubMedCrossRef
46.
Ozen S, Ben-Chetrit E, Bakkaloglu A, et al. Polyarteritis nodosa associated with familial mediterranean fever: is it an association? Semin Arthritis Rheu. 2001;30:281–7.CrossRef
47.
Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr. 2007;166:145–51.PubMedCrossRef
48.
Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203–11.PubMedCrossRef
49.
Dillon MJ, Eleftherious D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol. 2010;25:1641–52.PubMedCrossRef
50.
51.
Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedCrossRef
52.
Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int. 2011;In press.
53.
Fathalla BM, Miller L, Brady S, et al. Cutaneous polyarteritis nodosa in children. J Am Acad Dermatol. 2005;53:724–8.PubMedCrossRef
54.
David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child. 1993;69:685–8.PubMedCrossRef
55.
56.
Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–202.PubMedCrossRef
57.
Vamvakopoulos J, Savage CO, Harper L. ANCA-associated vasculitides—lessons from the adult literature. Pediatr Nephrol. 2010;25:1397–407.PubMedCrossRef
58.
Zwerina J, Eger G, Englbrecht M, et al. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patient. Semin Arthritis Rheum. 2008;39:108–15.PubMedCrossRef
59.
Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis & Rheumatism. 2007;52(5):837–44.CrossRef
60.
Vanoni F, Bettinelli A, Keller F, et al. Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol. 2010;25:205–12.PubMedCrossRef
61.
Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919–29.PubMed
62.
Sharma BK, Sagar S, Chugh KS, et al. Spectrum of renovascular hypertension in the young in north India. Angiology. 1985;36:370–8.PubMedCrossRef
63.
Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270–5.PubMedCrossRef
64.
Vanoli M, Daina E, Salvarini C, et al. Takayasu arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005;53:100–7.PubMedCrossRef
65.
Hahn D, Thomson PD, Kala U, et al. A review of Takayasu’s arteritis in children in Gauteng, South Africa. Pediatr Nephrology. 1998;12:668–75.CrossRef
66.
•• Morishita KA, Rosendahl K, Brogan P. Familial Takayasu arteritis—a pediatric case and a review of the literature. Pediatr Rheum. 2011;In press. This is a recent review of familial TA cases in the literature encouraging the search for candidate genes in TA pathogenesis.
67.
Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35:913–9.PubMed
68.
Yamada I, Nakagawa T, Himero Y, et al. Takayasu arteritis: diagnosis with breath hold contrast enhanced 3-dimensional MR angiography. J Magn Reson Imaging. 2000;II:481–7.CrossRef
69.
Koening CL, Langford CA. Novel therapeutic strategies for large vessel vasculitis. Rheum Dis Clin North Am. 2006;32:173–86.PubMedCrossRef
70.
Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150:72–6.PubMedCrossRef
71.
Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;12:16–24.CrossRef
72.
Lee GY, Jang SY, Ko SM, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol. 2011;In press.
73.
Ozen S. The ‘other’ vasculitic syndromes and kidney involvement. Pediatr Nephrol. 2010;25(9):1633–9.PubMedCrossRef
74.
Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58:3951–9.PubMedCrossRef
75.
Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study. Arthritis Rheum. 2009;61:600–4.PubMedCrossRef
76.
•• Ozen S. Pediatric onset Behçet disease. Curr Opin Rheumatol. 2010;22:585–89. This is a recent review of childhood Behçet’s syndrome. PubMedCrossRef
77.
• Fei Y, Webb R, Cobb BL, et al. Identification of novel genetic susceptibility loci for Behçet’s disease using a genome-wide association study. Arthritis Res Ther. 2009;11:R66. This was the first GWAS in Behçet’s syndrome. PubMedCrossRef
78.
Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMedCrossRef
79.
International Study Group for Behcet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.
80.
Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee, EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–62.PubMedCrossRef
81.
Cantarini L, Tinazzi I, Caramaschi P, et al. Safety and efficacy of etanercept in children with juvenile-onset Behcet’s disease. Int J Immunopathol Pharmacol. 2009;22:551–5.PubMed
Metadata
Title
Pediatric Vasculitis
Authors
Ezgi Deniz Batu
Seza Ozen
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 2/2012
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0232-4

Other articles of this Issue 2/2012

Current Rheumatology Reports 2/2012 Go to the issue

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Prevention and Management of Cataracts in Children with Juvenile Idiopathic Arthritis–Associated Uveitis

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

The Clinical Spectrum of Juvenile Idiopathic Arthritis in a Large Urban Population

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

What Do Cytokine Profiles Tell Us About Subsets of Juvenile Idiopathic Arthritis?

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Association Between Gout and All-Cause as well as Cardiovascular Mortality: A Systematic Review

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Current Understanding of the Pathogenesis and Management of Chronic Recurrent Multifocal Osteomyelitis

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Gout and Organ Transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits